DK0641325T3 - Inhibitorer af retroviral protease - Google Patents

Inhibitorer af retroviral protease

Info

Publication number
DK0641325T3
DK0641325T3 DK93911046T DK93911046T DK0641325T3 DK 0641325 T3 DK0641325 T3 DK 0641325T3 DK 93911046 T DK93911046 T DK 93911046T DK 93911046 T DK93911046 T DK 93911046T DK 0641325 T3 DK0641325 T3 DK 0641325T3
Authority
DK
Denmark
Prior art keywords
inhibitors
retroviral protease
chem
retroviral
protease
Prior art date
Application number
DK93911046T
Other languages
Danish (da)
English (en)
Inventor
Richard August Mueller
Gary Anthony Decrescenzo
John Nicholas Freskos
Donald Joseph Rogier Jr
Robert Martin Heintz
Michael Clare
Michael Lawrence Vazquez
Daniel Paul Getman
Ko-Chung Lin
Kathryn Lea Reed
John Jeffrey Talley
Original Assignee
Monsanto Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monsanto Co filed Critical Monsanto Co
Application granted granted Critical
Publication of DK0641325T3 publication Critical patent/DK0641325T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
DK93911046T 1992-05-21 1993-05-04 Inhibitorer af retroviral protease DK0641325T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88670092A 1992-05-21 1992-05-21
PCT/US1993/004208 WO1993023379A1 (en) 1992-05-21 1993-05-04 Retroviral protease inhibitors

Publications (1)

Publication Number Publication Date
DK0641325T3 true DK0641325T3 (da) 2001-04-17

Family

ID=25389564

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93911046T DK0641325T3 (da) 1992-05-21 1993-05-04 Inhibitorer af retroviral protease

Country Status (11)

Country Link
US (10) US5648364A (de)
EP (4) EP0957093A3 (de)
JP (1) JPH07508020A (de)
AT (1) ATE199545T1 (de)
AU (1) AU667376B2 (de)
CA (1) CA2136312A1 (de)
DE (1) DE69329996T2 (de)
DK (1) DK0641325T3 (de)
ES (1) ES2155069T3 (de)
GR (1) GR3035526T3 (de)
WO (1) WO1993023379A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878728B1 (en) 1999-06-11 2005-04-12 Vertex Pharmaceutical Incorporated Inhibitors of aspartyl protease
US20040122000A1 (en) 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
EP0565631B1 (de) * 1991-01-02 1996-09-18 Merrell Pharmaceuticals Inc. Antivirale verbindungen
EP0957093A3 (de) 1992-05-21 2000-04-12 Monsanto Company Retrovirusprotease Inhibitoren
US5783701A (en) 1992-09-08 1998-07-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
US5846993A (en) * 1992-12-22 1998-12-08 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
CA2166693C (en) * 1993-07-08 1999-08-24 Daniel Schirlin Difluoro statone analogs
HUT74569A (en) * 1993-09-09 1997-01-28 Merrell Pharma Inc Difluoro statone antiviral analogs, pharmaceutical compn. contg. them and process for preparing the said comds.
US5587514A (en) * 1993-11-08 1996-12-24 Emory University Diastereoselective synthesis of hydroxyethylene dipeptide isosteres
WO1995024385A1 (en) * 1994-03-07 1995-09-14 Vertex Pharmaceuticals Incorporated Sulphonamide derivatives as aspartyl protease inhibitors
US5527829A (en) * 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
EP0804428B1 (de) 1995-01-20 2007-12-26 G.D. Searle LLC. Bis-sulfonamid-hydroxyethylamino-derivate als inhibitoren retroviraler proteasen
US5691372A (en) * 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
US6004957A (en) * 1995-06-07 1999-12-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
US6114380A (en) * 1995-12-18 2000-09-05 Merrell Pharmaceuticals Inc. Difluoro statone analogs
US5962725A (en) 1996-09-05 1999-10-05 Agouron Pharmaceuticals, Inc. Intermediate compounds useful for making HIV protease inhibitors such as nelfinavir
US5925759A (en) 1996-09-05 1999-07-20 Agouron Pharmaceuticals, Inc. Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
US5705647A (en) * 1996-09-05 1998-01-06 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
DE19703713A1 (de) * 1997-01-23 1998-07-30 Hans Prof Dr Schick Verfahren für die Herstellung von Oxetan-2-onen und Zwischenprodukte
US6001851A (en) * 1997-03-13 1999-12-14 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US6084107A (en) * 1997-09-05 2000-07-04 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
ATE285396T1 (de) 1998-06-19 2005-01-15 Vertex Pharma Sulfonamide als aspartyl-protease-inhibitoren
US6538006B1 (en) 1998-07-08 2003-03-25 Pharmacia Corporation Retroviral protease inhibitors
WO2000006035A1 (en) * 1998-07-31 2000-02-10 Surx, Inc. Limited heat transfer devices and methods to shrink tissues
KR100277723B1 (ko) * 1998-12-14 2001-01-15 남창우 광학적으로 순수한 데카하이드로이소퀴놀린카르복사미드의 연속제조공정
CZ299699B6 (cs) * 1998-12-14 2008-10-22 Sk Corporation Zpusob výroby [3S-(3alfa, 4alfabeta, 8alfabeta)]-N-terc-butyl-dekahydro-3-izochinolinkarboxamidu s vysokým optickým výtežkem

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA9334A (en) * 1878-11-11 Josiah M. Simpson Improvements in boiler feeders
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
EP0068378B1 (de) * 1981-06-26 1986-03-05 Schering Corporation Imidazo(1,2-a)pyridine und -pyrazine, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
DE3377497D1 (en) * 1982-09-15 1988-09-01 Haessle Ab Enzyme inhibitors
EP0114993B1 (de) * 1982-12-27 1990-05-16 Merck & Co. Inc. Reninhemmende Tripeptide
US4668770A (en) * 1982-12-27 1987-05-26 Merck & Co., Inc. Renin inhibitory tripeptides
EP0118223A1 (de) * 1983-02-07 1984-09-12 Aktiebolaget Hässle Enzymhemmende Stoffe
JPS59227851A (ja) * 1983-06-09 1984-12-21 Sankyo Co Ltd レニン阻害作用を有するペプチド類
US4514391A (en) * 1983-07-21 1985-04-30 E. R. Squibb & Sons, Inc. Hydroxy substituted peptide compounds
US4477441A (en) * 1983-09-14 1984-10-16 Merck & Co., Inc. Renin inhibitors containing a C-terminal disulfide cycle
US4645759A (en) * 1984-06-22 1987-02-24 Abbott Laboratories Renin inhibiting compounds
JPS6173237A (ja) * 1984-09-18 1986-04-15 Hitachi Maxell Ltd 磁気デイスク
US4616088A (en) * 1984-10-29 1986-10-07 E. R. Squibb & Sons, Inc. Amino acid ester and amide renin inhibitor
US4688770A (en) * 1985-06-10 1987-08-25 V-K Enterprises, Inc. Guide assembly for cutting torch tip
US4668769A (en) * 1985-08-02 1987-05-26 Hoover Dennis J Oxa- and azahomocyclostatine polypeptides
US4599198A (en) * 1985-08-02 1986-07-08 Pfizer Inc. Intermediates in polypeptide synthesis
CA1282549C (en) * 1985-11-12 1991-04-02 Eric M. Gordon Aminocarbonyl renin inhibitors
CA1297631C (en) * 1985-12-23 1992-03-17 Sesha I. Natarajan Ureido renin inhibitors
US4757050A (en) * 1985-12-23 1988-07-12 E. R. Squibb Sons, Inc. Ureido renin inhibitors
US4880938A (en) * 1986-06-16 1989-11-14 Merck & Co., Inc. Amino acid analogs
DE3635907A1 (de) * 1986-10-22 1988-04-28 Merck Patent Gmbh Hydroxy-aminosaeurederivate
CH676988A5 (de) * 1987-01-21 1991-03-28 Sandoz Ag
USH725H (en) * 1987-02-26 1990-01-02 E. R. Squibb & Sons, Inc. Ureido amino and imino acids, compositions and methods for use
GB8707412D0 (en) * 1987-03-27 1987-04-29 Fujisawa Pharmaceutical Co Peptide compounds
DE3830825A1 (de) * 1987-09-15 1989-03-23 Sandoz Ag Hydrophile reninhemmer, ihre herstellung und verwendung
IL89900A0 (en) * 1988-04-12 1989-12-15 Merck & Co Inc Hiv protease inhibitors useful for the treatment of aids and pharmaceutical compositions containing them
US4977277A (en) * 1988-05-09 1990-12-11 Abbott Laboratories Functionalized peptidyl aminodiols and -triols 4-amino-5-cyclohexyl-3-hydroxy-1,2-oxopentane and derivatives thereof
IL90218A0 (en) * 1988-05-13 1989-12-15 Abbott Lab Retroviral protease inhibitors
CA1340588C (en) * 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
JP2512787B2 (ja) * 1988-07-29 1996-07-03 株式会社日立製作所 内燃機関のスロットル開度制御装置
IL91307A0 (en) * 1988-08-24 1990-03-19 Merck & Co Inc Hiv protease inhibitors and pharmaceutical compositions for the treatment of aids containing them
CA2012306A1 (en) * 1989-03-28 1990-09-28 Werner Neidhart Amino acid derivatives
JP2701932B2 (ja) * 1989-04-10 1998-01-21 サントリー株式会社 タンパク質分解酵素阻害剤
DE3912829A1 (de) * 1989-04-19 1990-10-25 Bayer Ag Verwendung von renininhibitorischen peptiden als mittel gegen retroviren
WO1991008221A1 (en) * 1989-12-04 1991-06-13 Wisconsin Alumni Research Foundation Peptide inhibitors of hiv protease
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
WO1992000750A1 (en) 1990-07-06 1992-01-23 Smithkline Beecham Corporation Retroviral protease inhibitors
EP0472077A3 (en) * 1990-08-24 1993-03-31 Bayer Ag Phosphonate containing hydroxyethylamin- and norstatin-type pseudopeptides
CA2052902A1 (en) * 1990-10-11 1992-04-12 Laszlo R. Treiber Inhibitor of hiv protease
CA2052907A1 (en) * 1990-10-11 1992-04-12 Joseph P. Vacca Hiv protease inhibitors having symmetrical structure
EP0480624A1 (de) * 1990-10-11 1992-04-15 Merck & Co. Inc. HIV Protease Hemmstoffe
JPH06505963A (ja) * 1990-11-19 1994-07-07 モンサント　カンパニー レトロウイルスプロテアーゼ阻害剤
EP0957093A3 (de) * 1992-05-21 2000-04-12 Monsanto Company Retrovirusprotease Inhibitoren
US5780455A (en) * 1994-08-24 1998-07-14 Merck & Co., Inc. Intravenous alendronate formulations
US5646364A (en) * 1995-06-19 1997-07-08 Donald Lee Chastain Explosive device for use in underwater demolition operations and method therefor

Also Published As

Publication number Publication date
US20030195227A1 (en) 2003-10-16
US20050004230A1 (en) 2005-01-06
CA2136312A1 (en) 1993-11-25
GR3035526T3 (en) 2001-06-29
EP0957093A2 (de) 1999-11-17
US20080103311A1 (en) 2008-05-01
DE69329996D1 (de) 2001-04-12
WO1993023379A1 (en) 1993-11-25
DE69329996T2 (de) 2001-09-06
ATE199545T1 (de) 2001-03-15
ES2155069T3 (es) 2001-05-01
US5643924A (en) 1997-07-01
US5648364A (en) 1997-07-15
US6762187B2 (en) 2004-07-13
US7312333B2 (en) 2007-12-25
EP1447398A1 (de) 2004-08-18
US6506759B1 (en) 2003-01-14
EP0641325A1 (de) 1995-03-08
US6180646B1 (en) 2001-01-30
US5756534A (en) 1998-05-26
AU4232793A (en) 1993-12-13
EP1148050A1 (de) 2001-10-24
EP0641325B1 (de) 2001-03-07
JPH07508020A (ja) 1995-09-07
US20060166895A1 (en) 2006-07-27
EP0957093A3 (de) 2000-04-12
AU667376B2 (en) 1996-03-21
US5948790A (en) 1999-09-07
US7026485B2 (en) 2006-04-11

Similar Documents

Publication Publication Date Title
DK0641325T3 (da) Inhibitorer af retroviral protease
DE69132435T2 (de) Inhibitoren retroviraler Proteasen
DK0481522T3 (da) Nye mercaptoacetylamid-derivater anvendelige som inhibitorer af enkephalinase og ACE
DE69527072T2 (de) Endothelin antagoniste
FI924311A (fi) Nya 2-substituerade indan-2-merkaptoacetylamidderivat anvaendbara som inhibitorer av enkefalinas och ace
TR200200129T2 (tr) Hepatit C inhibitörü tri-peptidler
FI932104A0 (fi) Nya 4-arylpiperaziner och 4-arylpiperidiner
FI914928A0 (fi) Hydroximetyl (metylencyklopentyl) puriner och -pyrimidiner.
NO931795D0 (no) Dobbeltvirkende inhibitorer
ATE179173T1 (de) 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy 1,3-propandiol-derivate
UY24625A1 (es) Derivados de la 4-hidroxi-piperidina
FI931855A (fi) Farmaceutisk sammansaettning som innehaoller kinolin- och kinazolinderivat samt nya foereningar daerfoer
SE9100920D0 (sv) New active compounds
DE69309454D1 (de) Pyridincarboximidamide und deren anwendung
FI962073A0 (fi) HIV-proteaasin estäjän prodrug-muotoja
NO934721D0 (no) Hemmere av HIV-protease som er nyttige for behandling av AIDS
UA26459C2 (uk) Іhгібітор впливу амілоїдhих білків
DK0417746T3 (da) N-Azabicyclo(3.3.0)octanamider af aromatiske syrer
DK0779075T3 (da) Anvendelse af 3-alpha-hydroxy-5-alpha-androsta-16-en som lægemidler